Dogwood Therapeutics, Inc. (DWTX) Key Metrics
DWTX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $41.5M
- Enterprise value
- $41.7M
- P/E (TTM)
- 0.6
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.7
- EV / EBITDA
- 0.2
- Dividend yield
- —
- Beta
- 1.94
DWTX key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsDWTX returns How much profit the business earns on the capital it uses.
DWTX financial health Debt, liquidity and how easily interest is covered.
DWTX valuation history
DWTX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
DWTX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
DWTX cash returned to shareholders
DWTX price vs earnings per share
DWTX key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $34.2M | — | — | — | — | — | — | — |
| Enterprise value | $27.8M | — | — | — | — | — | — | — |
| Price / book | 0.5 | — | — | — | — | — | — | — |
| Earnings yield | −100.2% | — | — | — | — | — | — | — |
| Free cash flow yield | −45.7% | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $4.16 | $2.49 | $14.38 | $5.90 | $127.88 | $187.75 | — | — |
| Per share | ||||||||
| Revenue per share | $0.00 | — | — | — | — | — | — | — |
| Earnings per share | −$4.17 | — | — | — | — | — | — | — |
| Operating cash flow per share | −$1.90 | — | — | — | — | — | — | — |
| Free cash flow per share | −$1.90 | — | — | — | — | — | — | — |
| Cash per share | $0.79 | — | — | — | — | — | — | — |
| Book value per share | $9.11 | — | — | — | — | — | — | — |
| Tangible book value per share | −$0.79 | — | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — | — |
| Debt per share | $0.02 | — | — | — | — | — | — | — |
| Shares outstanding | 8.2M | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −49.2% | −36.3% | −95.1% | −112.2% | −71.8% | −82.8% | — | — |
| Return on invested capital (ROIC) | −33.1% | −29.5% | — | — | — | — | — | — |
| Return on assets (ROA) | −37.1% | −25.1% | −84.5% | −101.4% | −67.6% | −65.1% | — | — |
| Return on tangible assets | −389.9% | −73.6% | −127.1% | −146.3% | −101.2% | −32.9% | −783.0% | — |
| Financial health | ||||||||
| Total debt | $162,604 | $15.6M | — | — | — | — | $3.6M | — |
| Cash & short-term investments | $6.5M | $14.8M | $3.3M | $7.0M | $14.0M | $29.8M | $309,384 | $30,026 |
| Net debt | −$6.4M | $737,709 | −$3.3M | −$7.0M | −$14.0M | −$29.8M | $3.3M | −$30,026 |
| Debt / equity | 0.00 | 0.24 | — | — | — | — | — | — |
| Debt / assets | 0.00 | 0.17 | — | — | — | — | 11.51 | — |
| Current ratio | 2.76 | 5.21 | 11.62 | 8.02 | 12.37 | 20.55 | 0.19 | 0.03 |
| Quick ratio | 2.76 | 5.21 | 11.62 | 8.02 | 12.37 | 20.55 | 0.19 | 0.03 |
| Interest coverage | — | -132.6 | — | — | — | -26.0 | -7.4 | -12.9 |
| Working capital | $5.4M | $13.4M | $3.8M | $7.3M | $14.5M | $29.9M | −$1.3M | −$1.3M |
| Invested capital | $68.5M | $65.0M | $489,948 | $295,502 | $492,880 | $145,523 | −$1.6M | −$1.3M |
| Tangible asset value | −$6.5M | −$13.2M | $3.8M | $7.3M | $14.5M | $29.9M | −$4.9M | −$1.3M |
| Net current asset value | −$6.8M | −$13.5M | $3.8M | $7.3M | $14.5M | $29.9M | −$4.9M | −$1.3M |
| Graham net-net per share | −$1.06 | — | — | — | — | — | — | — |
| Capital allocation | ||||||||
| Dividends paid | — | — | — | — | $0 | $75,000 | — | — |
| Share buybacks (net) | $0 | $351 | $0 | — | $295,166 | — | — | — |
| Capex / depreciation | 0.00 | 0.00 | — | — | — | — | — | — |
| Efficiency | ||||||||
| Days payables outstanding | — | 20,138.7 | — | — | — | — | — | — |
| Receivables turnover | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Payables turnover | — | 0.02 | — | — | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | — | — | — | $554 | $560 | $334 |
| Average payables | $996,375 | $671,859 | $342,538 | $463,514 | $361,384 | $202,163 | $90,538 | $145,656 |
| Intangibles / total assets | 90.3% | 82.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from DWTX's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
DWTX valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 0.6. Dogwood Therapeutics earned a return on equity of −49.2% and a return on invested capital of −33.1% in fiscal 2025. It ended the year with $0.2 million of debt and $6.5 million in cash and short-term investments, a net cash position of $6.4 million.
See the DWTX income statement, the DWTX chart for price history, or the DWTX stock overview for the latest quote and news.
DWTX key metrics FAQ
What is Dogwood Therapeutics's P/E ratio?
Dogwood Therapeutics's trailing P/E ratio is 0.6 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was —.
What is Dogwood Therapeutics's return on equity?
Dogwood Therapeutics's return on equity (ROE) was −49.2% in fiscal 2025: net income of -$34.3 million on average shareholders' equity of $69.6 million.
What is Dogwood Therapeutics's ROIC?
Dogwood Therapeutics's return on invested capital was −33.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Dogwood Therapeutics have?
Dogwood Therapeutics had total debt of $0.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Dogwood Therapeutics's free cash flow yield?
Dogwood Therapeutics generated -$15.6 million of free cash flow in fiscal 2025, a free cash flow yield of −45.7% on its market value at year-end ($34.2 million).
What is Dogwood Therapeutics's current ratio?
Dogwood Therapeutics's current ratio was 2.76 at the end of fiscal 2025: current assets were 2.76 times current liabilities.